Marksans Pharma Ltd
Dr. Vivek Mishra has an extensive work experience starting as a Senior Research Fellow at Council for Scientific and Industrial Research (CSIR) in 1999. Vivek later worked as a Research Scientist at Ranbaxy, followed by roles at Adina Institute of Science & Technology as an Associate Professor and the University of Alberta as a Postdoc Research Associate. Vivek then moved on to roles at Torrent Pharmaceuticals Ltd, SUN PHARMA, and Unichem Laboratories Limited, focusing on formulation development and research. Currently, Dr. Mishra holds the position of Head & Senior General Manager of Formulation Research and Development at Marksans Pharma Ltd. - India.
Vivek Mishra, PhD, holds a B.Pharm in Pharmaceutical Sciences from Doctor Harisingh Gour Vishwavidyalaya, an M.Pharm in Pharmaceutics (NDDS), and a Ph.D. in Pharmaceutics (NDDS) from the same university. Vivek also completed a Postdoc in Nanotechnology at the University of Alberta. In addition, they have obtained various certifications in topics such as Artificial Intelligence, Six Sigma, and Leadership Development.
This person is not in any teams
Marksans Pharma Ltd
Marksans Pharma Limited is a pharmaceutical holding company. The Company is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The Company's product portfolio addresses various therapeutic segments, including Pain management, Cough and cold, Anti-diabetic, Cardiovascular system, Central nervous system, Antibiotic, Gastrointestinal, Anti-allergic and Miscellaneous. The Company undertakes research and development initiatives, and offers customer relationship management (CRM) services to global pharmaceutical companies. The Company has a manufacturing facility for the manufacture of oral solid tablets and soft gelatin capsules in Goa; a liquids/ointments/sachets manufacturing facility in Southport, the United Kingdom, and a solid oral dosages manufacturing facility in New York, the United States. It supplies products to approximately 20 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd. and Marksans Pharma (UK) Limited.